CureVac Takes Another Shot At mRNA Vaccines, Expands Cancer Work
Wants To Compete With Neighbors BioNTech
Its first COVID-19 vaccine failed last year, but fueled by payments from the EU, Germany and GSK, CureVac is trying again with two further versions of its mRNA platform.
You may also be interested in...
CAR-T has revolutionized the treatment options for blood cancers but its application for solid tumors has fallen short. The German biotech hopes that by combining a CAR-T cell therapy with an mRNA vaccine could be a gamechanger.
The biotech has 15 pathogens in its sights and is also launching mRNA Access that will grant researchers the opportunity to use Moderna's technology platform to develop vaccines for emerging or neglected infectious diseases.
Beam is the latest allogeneic CAR-T developer to face a regulatory hold-up, but other candidates using its pioneering base-editing technology are now progressing.